We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Blocking Nerve Growth Factor Receptor Enables Human Nervous System Regeneration

By LabMedica International staff writers
Posted on 20 Aug 2014
The mystery of why the human nervous system is unable to regenerate may have been at least partially solved with the identification of a protein called p75 that seems to block the repair of damaged nerve cells.

Investigators at the Salk Institute for Biological Studies (La Jolla, CA, USA) explained that the p75 neurotrophin receptor, a member of the tumor necrosis factor receptor superfamily, was required as a co-receptor for the Nogo receptor (NgR - reticulon 4 receptor) to mediate the activity of regeneration inhibitors such as Nogo. More...
The Nogo receptor mediates axonal growth inhibition and may play a role in regulating axonal regeneration and plasticity in the adult central nervous system.

p75, also called nerve growth factor receptor, contains an extracellular domain containing four 40-amino acid repeats with six cysteine residues at conserved positions followed by a serine/threonine-rich region, a single transmembrane domain, and a 155-amino acid cytoplasmic domain. The cysteine-rich region contains the nerve growth factor binding domain.

In the current study, the investigators used a protein, p45, known to stimulate nervous system regeneration in lower animals but lacking in humans. They found that when added to cultures of human neurons, p45 markedly interfered with the function of p75 as a co-receptor for NgR. p45 bound p75 through both its transmembrane (TM) domain and death domain (DD).

To understand the underlying mechanisms, they determined the three-dimensional NMR solution structure of the intracellular domain of p45 and characterized its interaction with p75. They identified the residues involved in this interaction by NMR and co-immunoprecipitation.

Results of these structural and functional studies published in the August 5, 2014, online edition of the journal PLOS Biology revealed that p45 bound specifically to conserved regions in the p75 transmembrane domain and in the intracellular domain and that this binding blocked p75 dimerization along with its downstream signaling. Blocking the activity of p75 allowed nervous tissue to regenerate.

“This research implies that we might be able to mimic neuronal repair processes that occur naturally in lower animals, which would be very exciting,” said senior author Dr. Kuo-Fen Lee, professor of molecular neurobiology at the Salk Institute for Biological Studies. “We do not know why this nerve regeneration does not occur in humans. We can speculate that the brain has so many neural connections that this regeneration is not absolutely necessary.”

Related Links:

Salk Institute for Biological Studies



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Blood Glucose Reference Analyzer
Nova Primary
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.